The Ebola patient in Dallas who received an experimental Chimerix Inc. drug died Wednesday, but infectious-disease researchers keen for any new tool to fight the widening viral outbreak said it was premature to rule out the drug’s potential to treat Ebola.. The Chimerix drug, brincidofovir, is one of several experimental therapies that are being deployed against Ebola on a limited basis, in the absence of any approved Ebola-specific drugs or vaccines. Brincidofovir and the other drugs haven’t been tested in human studies against...
  